JAMA Network
About The Study: This proof-of-concept randomized clinical trial provides insights into the therapeutic potential of interleukin 6 (IL-6) or IL-6 receptor inhibition for depression and highlights suitable patient selection methods. Interleukin 6, a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
